Neuroprotective therapy for glaucoma

Written by Pnyukhtina M.S., Khvan D.A., Filina N.V.

  UDK: 617.7–007.681–085.216.84 | Pages: 5–8 | Full text PDF | Open PDF 


One of the most important problems in ophthalmology is a treatment of patients with primary glaucoma. Nowadays about 10–15 % patients with glaucoma, even with appropriate treatment, are doomed to be blind. Normalization of intraocular tension is obligatory but does not guarantee the stabilization of glaucoma development. Neuroprotective therapy is believed to be important and aimed at preserving not dead but destructed with the ischemia of the axons of the ganglionic nerve cells. The groups of drugs and methods of treatment possessing neuroprotective action in glaucoma, and the problems that arise with the practicing physician in the appointment of neuroprotectors, are examined.

Links to authors:

M.S. Pnyukhtina, D.A. Khvan, N.V. Filina
Pacific State Medical University (2 Ostryakova Ave. Vladivostok 690002 Russian Federation)

1. Alekseev V.N., Kozlova N.V. Retinalamin application in patients with primary open-angle glaucoma // National Journal glaucoma. 2013. No. 1. P. 49–52.
2. Astakhov Yu.S., Butin Ye.V., Morozova N.V. [et al.]. An experience of Retinalamin use in glaucomatous optic neuropathy and age-related macular degeneration // Ophthalmology Journal. 2013. No. 2. Р. 45–48
3. Astakhov Yu.S., Kiryanova V.V., Maksimov A.V. [et al.]. Retinalamin neuroprotective action assessment in treatment of primary open-angle glaucoma stages 1–2 by endonasal electrophoresis // Ophthalmology Journal. 2010. No. 4. P. 61–65.
4. Bezdetko P.A. Neuroprotective treatment of glaucoma // Ophthalmology – Science – Practice. 2014. No. 17. P. 26–27.
5. Dautova Z.A., Mitrofanova N.V. Application of the drug Emoxipine in the complex treatment of glaucoma // Practical Medicine. 2016. No. 2. P. 150–156.
6. Egorov E.A., Astakhov Y.S., Shuko A.G. National Glaucoma Guidelines. Moscow: GEOTAR Media, 2011. 279 р.
7. Egorova T.E. Possibilities of usage Tanakan in ophthalmology. Literary review // Clinical ophthalmology. 2009. No. 4. P. 148–150.
8. Kurysheva N.I. Glaucoma optical neuropathy. Moscow: MEDpress Inform, 2006. P. 95–121.
9. Kurysheva N.I. Secondary neuroprotection in case of glaucoma // Medical Council. 2008. No. 3–4. Р. 76–77.
10. Mikhalsky E.A., Lysyak I.V. Methods of glaucoma optic neuropathy treatment // Far East Medical Journal. 2009. No. 2. P. 126–129.
11. Mishchenko N.P., Fedoreev S.A., Dogadova L.P. The drug Histochrome in ophthalmology // Vestnik of the Far East Branch of the Russian Academy of Sciences. 2004. No. 3. P. 111–119.
12. Polunin G.S., Nuriyeva S.M., Bayandin D.L. [et al.]. Determination of the therapeutic efficacy of the domestic drug “Semax 0.1 %” for diseases of the optic nerve // Annals of Ophthalmology. 2000. No. 1. Р. 15–18.
13. Rozhko Yu.I., Krivun A.O. Neuroprotective action of cortecsin and retinalamin in treatment of patients with open-angle glaucoma // Kuban Scientific Medical Bulletin. 2011. No. 1. P. 131–135.
14. Suhareva L.A., Dushin N.V., Nazarova V.S. Neuropeptides’ effect on visual functions in glaucomatous neuropathy // National Journal glaucoma. 2008. No. 1. P. 33–36.
15. Tedeeva N.S., Melnikov V.Ya., Dogadova L.P. Using of histochrom in ophthalmology // Рacific Medical Journal. 2014. No. 4. P. 17–21.
16. Usova L.A., Kharchenko L.N., Chentsova O.B. Medical treatment of primary glaucoma. Moscow: MONIKI, 2014. 20 p.
17. Filina A.A. Antioxidant therapy of glaucoma in the light of modern data // Glaucoma at the turn of the millennium: results and prospects. Moscow, 1999. Р. 325–328
18. Хавинсон В.X., Трофимова С.В. Пептидные биорегуляторы в офтальмологии. СПб.: Фолиант, 2000. 48 с. Khavinson V.H., Trofimova S.V. Peptide bioregulators in ophthalmology. St. Petersburg: Folio, 2000. 48 р.
19. Shakhmardanova S.A., Gulevskaya O.N., Seletskaya V.V. [et al.]. Antioxidants: classification, pharmacological properties the use in the practice of medicine // Journal of Fundamental Medicine and Biology. 2016. No. 3. P. 4–10.
20. Gross R., Hensley S., Gao F. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of beta-blockers // Surv. Ophthalmol. 1999. Vol. 43 (Suppl.). P. 162–170.
21. Hollo G., Whitson J., Faulkner R. Betaxolol distribution to the retina, optic nerve head and choroids of the human eye following chronic topical administration of Betoptic // Ophthalmic. Res. 2001. Vol. 33. P. 153.
22. Liu C.J., Ко Y.C., Cheng C.Y. Effect of latanoprost 0,005 % and brimonidine tartrate 0,2 % on pulsatile ocular blood flow in normal tension glaucoma // Br. J. Ophthalmol. 2002. Vol. 86, No. 11. Р. 1236–1239.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.